

ASX ANNOUNCEMENT

17 May 2023

Anteris Technologies Granted Additional Utility Patent for Novel Transcatheter Heart Valve Replacement Technology

BRISBANE, Australia and **MINNEAPOLIS, USA**, Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR) is pleased to announce that the United States Patent and Trademark Office has issued another utility patent to the Company for the novel DurAVR™ transcatheter heart valve (THV).

DurAVR™ THV is a first-in-class biomimetic valve uniquely designed to mimic the performance of a healthy human heart valve. The patent number 11,648,107 expires 12 September 2038, and provides additional Intellectual Property (IP) protection for the differentiated heart valve technology. This patent covers new claims that are additive to the existing IP coverage for DurAVR™ THV and protects the innovative single-piece tissue design with molded leaflets and commissures attached to a frame. The Company believes the unique aspects of the DurAVR™ design, including the single-piece valve construction and leaflet design, account for the excellent clinical results to date. This new patent confirms the Company's ability to build a broad IP portfolio around DurAVR™ THV.

“The awarding of this patent continues to highlight our culture of innovation and the extraordinary work by our team of engineers around the world responsible for the design of DurAVR™ THV. This new patent further enhances our broad IP protection for DurAVR™ THV and strengthens our competitive position in the TAVR field,” said Wayne Paterson, CEO.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



For more information:

Investor contact

Deanne Curry

GRACosway

E: investors@anteristech.com

M: +61 414 388 997

Media contact

Nick Howe

GRACosway

nhowe@gracosway.com.au

M: +61 407 183 221

www.anteristech.com

Twitter: [@AnterisTech](https://twitter.com/AnterisTech)

Facebook: www.facebook.com/AnterisTech

LinkedIn: <https://www.linkedin.com/company/anteristech>